- Home
- MCY vs DNLI Comparison
MCY vs DNLI Comparison
Compare MCY & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCY
- DNLI
- Stock Information
- Founded
- MCY 1961
- DNLI 2013
- Country
- MCY United States
- DNLI United States
- Employees
- MCY N/A
- DNLI N/A
- Industry
- MCY Property-Casualty Insurers
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCY Finance
- DNLI Health Care
- Exchange
- MCY Nasdaq
- DNLI Nasdaq
- Market Cap
- MCY 3.7B
- DNLI 3.8B
- IPO Year
- MCY N/A
- DNLI 2017
- Fundamental
- Price
- MCY $68.15
- DNLI $27.59
- Analyst Decision
- MCY
- DNLI Strong Buy
- Analyst Count
- MCY 0
- DNLI 10
- Target Price
- MCY N/A
- DNLI $38.22
- AVG Volume (30 Days)
- MCY 257.3K
- DNLI 773.7K
- Earning Date
- MCY 10-29-2024
- DNLI 11-05-2024
- Dividend Yield
- MCY 1.86%
- DNLI N/A
- EPS Growth
- MCY N/A
- DNLI N/A
- EPS
- MCY 5.76
- DNLI N/A
- Revenue
- MCY $5,018,905,000.00
- DNLI $1,267,000.00
- Revenue This Year
- MCY N/A
- DNLI N/A
- Revenue Next Year
- MCY $9.83
- DNLI $176.62
- P/E Ratio
- MCY $11.82
- DNLI N/A
- Revenue Growth
- MCY 18.32
- DNLI N/A
- 52 Week Low
- MCY $29.23
- DNLI $14.56
- 52 Week High
- MCY $68.84
- DNLI $32.13
- Technical
- Relative Strength Index (RSI)
- MCY 69.52
- DNLI 50.25
- Support Level
- MCY $62.09
- DNLI $26.49
- Resistance Level
- MCY $66.20
- DNLI $28.07
- Average True Range (ATR)
- MCY 1.76
- DNLI 1.03
- MACD
- MCY 0.39
- DNLI -0.23
- Stochastic Oscillator
- MCY 89.91
- DNLI 52.62
About MCY Mercury General Corporation
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.